H5N1 VLP vaccine: Phase II started

Medicago began a placebo-controlled Phase II trial to evaluate its intramuscular H5N1 VLP vaccine plus an alum adjuvant or Glucopyranosyl Lipid A (GLA-AF) adjuvant in 390 healthy adults ages 18-60 yea...